Trials / Active Not Recruiting
Active Not RecruitingNCT04829383
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
A Phase II Study of Atezolizumab and Bevacizumab in Child-Pugh B7 and B8 Hepatocellular Carcinoma (The AB7 Trial)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Howard S Hochster · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | 1,200 mg |
| DRUG | Bevacizumab | 15 mg/kg |
Timeline
- Start date
- 2021-03-22
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
- First posted
- 2021-04-02
- Last updated
- 2025-04-13
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04829383. Inclusion in this directory is not an endorsement.